4 results
- To examine the safety and feasibility (i.e. technical end result) of using OviTex core PGA during VMR - To assess perioperative complications- To assess 90-day morbidity
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
Main study parameter/endpoint phase II- Post-operative morbidity measured by reoperations, reinterventions, re-admissions, serious adverse events, Clavien Dindo classification and CTS classification. - The rate of rectal prolapse recurrence and…
Primary objective:Compare overall survival for subjects treated with docetaxel versus subjects treated with docetaxel plus raduim-223Secondairy objectives:To compare:a. Radiographic progression free survival as defined in PCWG3 criteria;b.…